Which data are needed to monitor site variability in eligibility screening?
Correct Answer: B
To monitor site variability in eligibility screening, you must analyze the number of subjects screened versus the number of subjects enrolled at each site. This allows identification of sites that are over- or under-screening relative to their enrollment yield. The GCDMP (Chapter: Data Quality Assurance and Metrics) emphasizes that screening-to-enrollment ratios are critical indicators of protocol compliance and data quality. Sites with unusually low conversion rates may have unclear understanding of inclusion/exclusion criteria, requiring targeted training or monitoring. Other options (A, C, D) provide enrollment metrics but do not reveal screening efficiency or variability, which depend on both screening and enrollment data. Thus, option B correctly identifies the data necessary for monitoring eligibility screening performance across sites. Reference (CCDM-Verified Sources): SCDM GCDMP, Chapter: Data Quality Assurance and Metrics, Section 5.4 - Site Performance Metrics ICH E6(R2) GCP, Section 5.18 - Monitoring and Site Oversight Requirements
Question 22
Which is the best way to identify sites with high subject attrition?
Correct Answer: A
The best method to identify sites with high subject attrition is to calculate the proportion of patients for which two visit periods have passed without data, by site. According to the GCDMP (Chapter: Data Quality Assurance and Control), subject attrition is an important performance indicator for data completeness and site compliance. Evaluating missing or delayed data across multiple consecutive visit periods allows for early detection of potential dropouts or site-level operational issues. By assessing this proportion at the site level, the Data Manager can distinguish between random missing data and systematic site underperformance. Counting or proportioning late visits (options B and C) identifies scheduling delays, not attrition. Looking at missing data without site context (option D) fails to identify site-specific patterns, limiting corrective action. This metric aligns with risk-based monitoring (RBM) practices recommended by ICH E6 (R2) and FDA RBM Guidance, which promote proactive identification of sites at risk of data loss. Reference (CCDM-Verified Sources): SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Quality Assurance and Control, Section 5.4 - Site Performance Metrics ICH E6 (R2) Good Clinical Practice, Section 5.18 - Monitoring and Site Performance Evaluation FDA Guidance for Industry: Oversight of Clinical Investigations - Risk-Based Monitoring, Section 6 - Site Performance Metrics
Question 23
What is the main reason 21 CFR Part 11 requires that EDC systems maintain an audit trail?
Correct Answer: A
The primary purpose of maintaining an audit trail as required under 21 CFR Part 11 is to preserve data integrity. According to the U.S. FDA's regulation on electronic records and signatures, every change to electronic data must be traceable, including information about who made the change, when it was made, and what the change entailed. The Good Clinical Data Management Practices (GCDMP) outlines that an audit trail provides a permanent, chronological record of all modifications to clinical data. This ensures transparency and allows the reconstruction of the course of data entry and modification. The regulation aims to prevent unauthorized or undocumented data manipulation, thereby maintaining the accuracy, reliability, and validity of electronic records. The FDA 21 CFR Part 11, Section 11.10(e) explicitly mandates that systems must use secure, computer-generated, time-stamped audit trails to independently record the date and time of operator entries and actions that create, modify, or delete electronic records. This ensures the data remains trustworthy and defensible in regulatory reviews or inspections. Therefore, the main reason for requiring an audit trail is to preserve data integrity - ensuring that all data captured, modified, or transmitted is authentic, accurate, and complete throughout the study lifecycle. Reference (CCDM-Verified Sources): SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Regulatory Compliance and Data Integrity FDA 21 CFR Part 11 - Electronic Records; Electronic Signatures, Section 11.10(e) ICH E6 (R2) Good Clinical Practice, Section 5.5.3 - Data Integrity and System Validation
Question 24
What does 21 CFR Part 11 dictate in regards to a minimum expectation of EDC training prior to access?
Correct Answer: A
Under FDA 21 CFR Part 11, organizations using electronic systems must ensure that all system users are trained to perform their assigned functions before gaining access to the system. The regulation requires documented evidence of training but does not specify how it should be conducted (e.g., exam-based, in person, or language-specific). The GCDMP (Chapter: Computerized Systems and Compliance) further clarifies that personnel training should include instruction on system functionality, audit trails, data entry procedures, and electronic signatures to maintain compliance and data integrity. Training must be performed and documented but does not require a specific format or delivery method. Therefore, option A-Training must be performed-is correct, as it reflects the minimum regulatory expectation per FDA and SCDM standards. Reference (CCDM-Verified Sources): FDA 21 CFR Part 11, Section 11.10(i) - Personnel Training Requirements SCDM GCDMP, Chapter: Computerized Systems and Compliance, Section 5.4 - System Training and Documentation ICH E6(R2) GCP, Section 2.8 - Qualified Personnel and Training Requirements
Question 25
A Data Manager is asked to manage SOPs for a department. Given equal availability of the following systems, which of the following is the best choice for managing the organizational SOPs?
Correct Answer: A
The best choice for managing Standard Operating Procedures (SOPs) in a compliant and auditable manner is a Document Management System (DMS). According to the GCDMP (Chapter: Regulatory Requirements and Compliance) and ICH E6 (R2), SOPs must be version-controlled, securely stored, retrievable, and auditable. A validated DMS supports controlled access, document lifecycle management (draft, review, approval, and archival), and electronic audit trails, ensuring full compliance with FDA 21 CFR Part 11 and Good Documentation Practices (GDP). While Learning Management Systems (C) track training, they are not intended for document control. Spreadsheets (B) and paper systems (D) cannot provide adequate version tracking, access security, or audit capability required for regulatory inspection readiness. Reference (CCDM-Verified Sources): SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Regulatory Requirements and Compliance, Section 5.2 - SOP Management and Document Control ICH E6 (R2) GCP, Section 5.5.3 - Document and Record Management FDA 21 CFR Part 11 - Electronic Records and Signatures, Section 11.10 - System Validation and Document Controls
